MedPath

To find out effect of Injection Zoledronic acid for treatment of bone weakening condition in patients having long term liver problems/damage.

Not Applicable
Completed
Conditions
Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Registration Number
CTRI/2020/03/024247
Lead Sponsor
Pt BD Sharma PGIMS Rohtak
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
49
Inclusion Criteria

Either gender adult patients with Osteoporosis with liver cirrhosis

Exclusion Criteria

Hyperparathyroidism

Acute Kidney Injury

Diabetes, Chronic kidney disease

Patients on corticosteroids, antiepileptics, antitubercular drugs

Hyperparathyroidism, malabsorption disorders

Thyroid disorders

Hepatocellular carcinoma/ any other malignancy Postmenopausal, pregnant/lactating

females

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Changes in Bone mineral Density <br/ ><br>2. Fracture risk assessment score (FRAX Score)Timepoint: 1 year
Secondary Outcome Measures
NameTimeMethod
1. Incidence of pathological fracture <br/ ><br>2. Effect on quality of life using IOF Quellafo 41, EQ 5D-3L, EQ VAS questionnaires <br/ ><br>3. Changes in biochemical parameters- Vitamin D levels, ALP, 24hours urone calcium levels. <br/ ><br>Timepoint: 1. 1 year <br/ ><br>2. 1 years <br/ ><br>3. 3,6,9,12 months.
© Copyright 2025. All Rights Reserved by MedPath